Here are the 424B prospectus supplements from Humacyte, Inc. Warrant (HUMAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow HUMAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full HUMAW filings page.
Humacyte, Inc. is offering 47,619,048 shares of its common stock pursuant to this prospectus supplement, at a public offering price of $1.05 per share (underwriters have a 30‑day option to purchase an additional 7,142,857 shares). The offering's gross proceeds are stated as $50,000,000.40, with estimated net proceeds to the company of approximately $47.0 million before expenses (approximately $53.85 million if the underwriters fully exercise their option).
The company reports that shares outstanding after the offering would be 269,638,156 (or 276,781,013 if the option is fully exercised). The prospectus supplement also discloses recently announced positive top-line interim results from the V012 Phase 3 trial, meeting its primary endpoint, and states an intention to submit a supplemental BLA in the second half of 2026. The company notes substantial doubt about its ability to continue as a going concern absent additional financing.
Humacyte, Inc. filed a preliminary prospectus supplement to offer shares of common stock (number and price not specified in the excerpt) and granted underwriters a 30-day option to purchase additional shares. Net proceeds are intended to fund Symvess commercialization, a planned supplemental BLA filing for hemodialysis, pipeline development and working capital.
The supplement also discloses positive top-line interim results from the V012 Phase 3 trial: ATEV patients averaged 220 catheter-free days versus 129 for AV fistula (p=0.00070), with infection rates of 6 vs. 23 per 100 patient-years. The company plans a supplemental BLA submission in the second half of 2026. Management reports available cash and equity capacity that fund operations into the first quarter of 2027 but states there is substantial doubt about its ability to continue as a going concern without additional financing.